Clinical trial
A Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Cresemba to Evaluate Safety and Effectiveness in Patients With Invasive Aspergillosis or Invasive Mucormycosis in Korea.
NCT04744454 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Cresemba to Evaluate Safety and Effectiveness in Patients With Invasive Aspergillosis or Invasive Mucormycosis in Korea.
- Lead sponsor
- Pfizer
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 28, 2021
- Completion date
- January 13, 2026
- Enrollment
- 94 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.